Join
Live feed
·
PRReleasevia Quantisnow
Connect Biopharma Holdings Limited logo

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
CNTB· Connect Biopharma Holdings Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CNTB (Connect Biopharma Holdings Limited) and more on Quantisnow.